This presentation establishes what makes UZEDY different from other LAIs, including a review of distinguishing pharmacokinetic and administration related features. Key efficacy and safety are reviewed along with the once-monthly and once-every-two-month dosing options for UZEDY.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
Ilan Melnick, MD
View biographical information
Ilan Melnick, MD
Chief Medical Officer, Passageway Adult Mental Health; Miami, FL; Medical Director, Jewish Community Services of South Florida - Mental Health Service; Miami, FL
Learning Objectives
- Understand the role of UZEDY as a long-acting injectable (LAI) treatment option for schizophrenia
- Discuss the flexible once-monthly and once-every-2-months dosing options of UZEDY
- Review the attributes of UZEDY, including initiation without loading dose or oral supplementation
Continuing Education Credit and Disclosures
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.